论文部分内容阅读
目的探讨两种不同控制血糖的治疗方案对初诊断Ⅱ型糖尿病相关指标的影响。方法105例初诊断Ⅱ型糖尿病患者分为口服药物治疗组和胰岛素治疗组,胰岛素使用双相门冬胰岛素30注射液,早、晚餐前皮下注射,口服药物使用常规降糖药物,均观察3个月,治疗前后测定空腹血糖(FPG)、餐后1、2h血糖(1hPG、2hPG)、糖化血红蛋白(HbAlc)、空腹及餐后2h胰岛素(Ins)、C-肽(C-P),并计算胰岛素抵抗指数(HOMA-IR)和胰岛β细胞分泌指数(HOMA-β)。结果胰岛素治疗组空腹血糖、餐后2h血糖(2hPG)、糖化血红蛋白(HbAlc)、空腹及餐后2h胰岛素(Ins)、C-肽(C-P),胰岛素抵抗指数(HOMA-IR)和胰岛β细胞分泌指数(HOMA-β)、血糖、糖化血红蛋白达标率均较口服药治疗组具有显著性差异。结论初诊断Ⅱ型糖尿病患者应用胰岛素治疗,尽快使血糖、糖化血红蛋白达标,减轻胰岛素抵抗,恢复胰岛β细胞的功能。
Objective To investigate the effects of two different blood glucose control regimens on the newly diagnosed type 2 diabetes mellitus. Methods 105 newly diagnosed patients with type Ⅱ diabetes mellitus were divided into two groups: oral drug treatment group and insulin treatment group. Insulin was administered with insulin aspart aspart 30 injection, subcutaneous injection before breakfast and dinner, oral administration of conventional antidiabetic drugs were observed in 3 Fasting blood glucose (FPG), postprandial 1,2h blood glucose (1hPG, 2hPG), HbAlc, fasting and postprandial 2h insulin and C-peptide were measured before and after treatment. Insulin resistance Index (HOMA-IR) and pancreatic β-cell secretion index (HOMA-β). Results The fasting blood glucose, 2hPG, HbAlc, fasting and postprandial 2h Ins, C-peptide, insulin resistance index (HOMA-IR) and islet βcells Secretion index (HOMA-β), blood glucose, glycosylated hemoglobin compliance rate than the oral medication group had significant differences. Conclusion Early diagnosis of type 2 diabetes patients with insulin treatment, as soon as possible to blood glucose, glycosylated hemoglobin standard, reduce insulin resistance, restore the function of islet β cells.